There is a clear need to have available anti-malarial drugs with targets different from those affected by agents for which resistance is widespread in the field. Because of the critical role played by mitochondria in eukaryotic organisms, they could form such targets. The challenge is to find compounds that affect the parasite mitochondrial physiology without affecting the host mitochondria. We previously identified several aspects of mitochondrial genetics and biochemistry of malaria parasites that could potentially be affected in a selective manner. Atovaquone, a newly developed broad-spectrum anti-parasite drug, selectively inhibits electron transport in malarial mitochondria, and was shown to collapse electropotential across the inner mitochondrial membrane in the parasites. Atovaquone as a single agent leads to unacceptable level of treatment failure, requiring the inclusion of synergistic drug, proguanil. Our investigations have provided clues as to the mechanism for this synergy, and a potential explanation for the relative lack of resistance emergence. To continue our investigations, we propose experiments that will extend the understanding of anti-mitochondrial drug action and resistance, and derive a more detailed view of mitochondrial physiology in malaria parasites. Mechanisms of drug action and resistance will be investigated by using genetic and biochemical tools that have been developed in our laboratory. The Malaria Genome Project is fast approaching completion of the entire DNA sequence of Plasmodium falciparum, and to use this information for further insights into mitochondrial physiology of the parasites, nuclearly encoded mitochondrial genes will be identified and their expression patterns will be determined. To develop tools for studying mitochondrial physiology in malaria parasites, genetic approaches will be used to identify signal sequences that direct nuclearly encoded proteins to the malarial mitochondria. These tools will be valuable for experimental testing of hypotheses regarding mitochondrial functions in malaria parasites. In summer, an integrated approach is proposed to develop a mechanistic and functional view of mitochondrial physiology of malaria parasites.. The approach of selective targeting parasite mitochondrion by anti-parasitic drugs has been established by the advent of atovaquone. Our proposed studies will derive better mechanistic insights into drug action to help future drug development strategies. The studies proposed will also provide basic information on parasite mitochondrial functions with a hope that these too can form the basis from which other effective means for malaria treatment can be developed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI028398-12
Application #
6212193
Study Section
Special Emphasis Panel (ZRG1-EVR (01))
Program Officer
Fairfield, Alexandra
Project Start
1989-07-01
Project End
2005-07-31
Budget Start
2000-08-01
Budget End
2001-07-31
Support Year
12
Fiscal Year
2000
Total Cost
$380,000
Indirect Cost
Name
Mcp Hahnemann University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19102
Vaidya, Akhil B (2018) Reflections on an inflection: From virology to parasitology guided by POLARIS. PLoS Pathog 14:e1006941
Ke, Hangjun; Dass, Swati; Morrisey, Joanne M et al. (2018) The mitochondrial ribosomal protein L13 is critical for the structural and functional integrity of the mitochondrion in Plasmodium falciparum. J Biol Chem 293:8128-8137
Bushell, Ellen; Gomes, Ana Rita; Sanderson, Theo et al. (2017) Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Cell 170:260-272.e8
Ke, Hangjun; Morrisey, Joanne M; Qu, Shiwei et al. (2017) Caged Garcinia Xanthones, a Novel Chemical Scaffold with Potent Antimalarial Activity. Antimicrob Agents Chemother 61:
Frueh, Lisa; Li, Yuexin; Mather, Michael W et al. (2017) Alkoxycarbonate Ester Prodrugs of Preclinical Drug Candidate ELQ-300 for Prophylaxis and Treatment of Malaria. ACS Infect Dis 3:728-735
Jenkins, Bethany J; Daly, Thomas M; Morrisey, Joanne M et al. (2016) Characterization of a Plasmodium falciparum Orthologue of the Yeast Ubiquinone-Binding Protein, Coq10p. PLoS One 11:e0152197
Stickles, Allison M; Smilkstein, Martin J; Morrisey, Joanne M et al. (2016) Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria. Antimicrob Agents Chemother 60:4853-9
Miley, Galen P; Pou, Sovitj; Winter, Rolf et al. (2015) ELQ-300 prodrugs for enhanced delivery and single-dose cure of malaria. Antimicrob Agents Chemother 59:5555-60
Stickles, Allison M; Ting, Li-Min; Morrisey, Joanne M et al. (2015) Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy. Am J Trop Med Hyg 92:1195-201
Ke, Hangjun; Lewis, Ian A; Morrisey, Joanne M et al. (2015) Genetic investigation of tricarboxylic acid metabolism during the Plasmodium falciparum life cycle. Cell Rep 11:164-74

Showing the most recent 10 out of 30 publications